Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures

Arthritis and Rheumatism

Volumn 40, Issue 1, 1997, Pages 164-174

  Didem Kozaci, L ^a   Buttle, David J ^a   Hollander, Anthony P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; COLLAGENASE; INTERLEUKIN 1ALPHA; MATRIX METALLOPROTEINASE; PROTEOGLYCAN;

ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE DEGENERATION; CATTLE; COLLAGEN DEGRADATION; ENZYME ACTIVITY; IMMUNOASSAY; IMMUNOBLOTTING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; CARTILAGE; CATTLE; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; IMMUNOBLOTTING; INTERLEUKIN-1; JOINTS; METALLOENDOPEPTIDASES; NASAL SEPTUM; ORGAN CULTURE TECHNIQUES; PROTEOGLYCANS; RECOMBINANT PROTEINS;

EID: 1842365544     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400121     Document Type: Article

References (47)

1. Kempson G: The mechanical properties of articular cartilage. In, The Joints and Synovial Fluid. Vol. 2. Edited by L Sokoloff. New York, Academic Press Inc., 1980
2. Poole AR: Cartilage in health and disease. In, Arthritis and Allied Conditions: A Textbook of Rheumatology. Edited by DJ McCarty, WJ Koopman. Philadelphia, Lea & Febiger, 1993
3. Hollander AP, Atkins RM, Eastwood DM, Dieppe PA, Elson CJ: Human cartilage is degraded by rheumatoid arthritis synovial fluid but not by recombinant cytokines in vitro. Clin Exp Immunol 83:52-57, 1991
4. Sandy JD, Flannery CR, Neame PJ, Lohmander LS: The structure of aggrecan fragments in human synovial fluid. J Clin Invest 89:1512-1516, 1992
5. Lohmander LS, Neame PJ, Sandy JD: The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 36:1214-1222, 1993
6. Lohmander LS: The release of aggrecan fragments into synovial fluid after joint injury and in osteoarthritis. J Rheumatol 22 (suppl 43):75-77, 1995
7. Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, Poole AR: Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 93:1722-1732, 1994
8. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR: Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest 96:2859-2869, 1995
9. Gross J, Nagai Y: Specific degradation of the collagen molecule by tadpole collagcnolytic enzyme. Proc Natl Acad Sci U S A 54:1197-1204, 1965
10. Gross J, Highberger JH, Johnson-Wint B, Biswas D: Mode of action and regulation of tissue collagenase. In, Collagenase in Normal and Pathological Connective Tissues. Edited by DE Woolley, JM Evanson. Chichester, UK, Wiley, 1980
11. Buttle DJ, Bramwell H, Hollander AP: Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy? J Clin Pathol Mol Pathol 48:M167-M177, 1995
12. Wu J-J, Lark MW, Chun LE, Eyre DR: Sites of stromelysin cleavage in collagen types II, IX, X and XI. J Biol Chem 266:5625-5628, 1991
13. Flannery CR, Lark MW, Sandy JD: Identification of a stromelysin cleavage site within the interglobulin domain of human aggrecan. J Biol Chem 267:1008-1014, 1992
14. Hardingham TE, Fosang AJ: The structure of aggrecan and its turnover in cartilage. J Rheumatol 22 (suppl 43):86-90, 1995
15. Lark M, Gordy JT, Weidner JR, Ayala J, Kimura JH, Williams HR, Mumford RA, Flannery CR, Carlson SS, Iwata M, Sandy JD: Cell-mediated catabolism of aggrecan. J Biol Chem 270:2550-2556, 1995
16. Singer II, Kawka DW, Bayne EK, Donatelli SA, Weidner JR, Williams HR, Ayala JM, Mumford RA, Lark MW, Giant TT, Nabozny GH, David CS: VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J Clin Invest 95:2178-2186, 1995
17. Sandy JD, Neame PJ, Boynton RE, Flannery CR: Catabolism of aggrecan in cartilage expiants. J Biol Chem 266:8683-8685, 1991
18. Freije JMP, Díez-Itza I, Balbín M, Sánchez LM, Blasco R, Tolivia J, López-Otín C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269:16766-16773, 1994
19. Murphy G, Reynolds JJ: Extracellular matrix degradation. In, Connective Tissue and Its Heritable Disorders: Molecular, Genetic and Medical Aspects. Edited by PM Royce, B Steinmann. New York, Wiley-Liss, Inc., 1993
20. Murphy GJP, Murphy G, Reynolds JJ: The origin of matrix metalloproteinases and their familial relationships. FEBS Lett 289:4-7, 1991
21. Rawlings ND, Barrett AJ: Evolutionary families of metallopeptidases. Methods Enzymol 248:183-228, 1995
22. Woessner JF Jr, GunjaSmith Z: Role of metalloproteinases in human osteoarthritis. J Rheumatol 18:99-101, 1991
23. Krakauer T, Oppenheim JJ, Jasin HE: Human interleukin 1 mediates cartilage matrix degradation. Cell Immunol 91:92-99, 1985
24. Goldring MB, Fukuo K, Birkhead JR, Dudek E, Sandell LJ: Transcriptional suppression by interleukin-1 and interferon γ of type II collagen gene expression in human chondrocytes. J Cell Biochem 54:85-99, 1994
25. 2 on chondrogenesis and cartilage matrix breakdown in vitro. Rheumatol Int 14:191-199, 1995
26. Arner EC, Tortorella MD: Signal transduction through chondrocyte integrin receptors induces matrix metalloproteinase synthesis and synergizes with interleukin-1. Arthritis Rheum 38:1304-1314, 1995
27. Buttle DJ, Handley CJ, Ilic MZ, Saklatvala J, Murata M, Barrett AJ: Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases: evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum 36:1709-1717, 1993
28. Ellis AJ, Curry VA, Powell EK, Cawston TE: The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem Biophys Res Commun 201:94-101, 1994
29. Xu C, Oyajobi BO, Frazer A, Kozaci LD, Russell RGG, Hollander AP: Effects of growth factors and interleukin-1α on proteoglycan and type II collagen turnover in bovine nasal and articular chondrocyte pellet cultures. Endocrinology 137:3557-3565, 1996
30. Brown CJ, Rahman S, Morton AC, Beauchamp CL, Bramwell H, Buttle DJ: Inhibition of cartilage explant proteoglycan breakdown by selective inhibitors of matrix metalloproteinases. J Clin Pathol Mol Pathol (in press)
31. Handley CJ, Buttle DJ: Assay of proteoglycan degradation. Methods Enzymol 248:47-58, 1995
32. Knight CG, Willenbrock F, Murphy G: A novel coumarin-labelled peptide for sensitive continuous assay of the matrix metalloproteinases. FEBS Lett 296:263-266, 1992
33. Rawlings ND, Barrett AJ: FLUSYS: a software package for the collection and analysis of kinetic and scanning data from Perkin-Elmer fluorimeters. Comput Appl Biosci 6:118-119, 1990
34. 14C]acetylated collagen. Anal Biochem 99: 340-345, 1979
35. Woessner JF Jr: Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol 248:510-528, 1995
36. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE: Cloning, expression and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 97:761-768, 1996
37. Goldring MB, Birkhead JR, Suen L-F, Yamin R, Mizuno S, Glowacki J, Arbiser JL, Apperley JF: Interleukin-1β-modulated gene expression in immortalized human chondrocytes. J Clin Invest 94:2307-2316, 1994
38. Chandrasekhar S, Harvey AK: Differential regulation of metallo-protease steady-state mRNA levels by IL-1 and FGF in rabbit articular chondrocytes. FEBS Lett 296:195-200, 1992
39. Hembry RM, Bagga MR, Dingle JT, Page Thomas P, Reynolds JJ: Metalloproteinase production by rabbit articular cartilage: comparison of the effects of interleukin-1α in vitro and in vivo. Virchows Arch 425:413-424, 1994
40. Nguyen Q, Mort JS, Roughley PJ: Preferential mRNA expression of prostromelysin relative to procollagenase and in situ localization in human articular cartilage. J Clin Invest 89:1189-1197, 1992
41. Salter DM, Hughes DE, Simpson R, Gardner DL: Integrin expression by human articular chondrocytes. Br J Rheumatol 31:231-234, 1992
42. Ginsberg MH, Xiaoping D, Plow EF: Inside-out integrin signalling. Curr Opin Cell Biol 4:766-771, 1992
43. Lefebvre V, Peeters-Joris C, Vaes G: Production of gelatin-degrading matrix metalloproteinases ('type IV collagenases') and inhibitors by articular chondrocytes during their dedifferentiation by serial subcultures and under stimulation by interleukin-1 and tumour necrosis factor α. Biochem Biophys Acta 1094:8-18, 1991
44. Knäuper V, Löpez-Otin C, Smith B, Knight G, Murphy G: Biochemical characterization of human collagenase-3. J Biol Chem 271:1544-1550, 1996
45. Meats JE, Elford PR, Bunning RAD, Russell RGG: Retinoids and synovial factor(s) stimulate the production of plasminogen activator by cultured human chondrocytes: a possible role for plasminogen activator in the resorption of cartilage in vitro. Biochem Biophys Acta 838:161-169, 1985
46. Bunning RAD, Crawford A, Richardson HJ, Opdenakker G, van Damme J, Russell RGG: Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes. Biochem Biophys Acta 924:473-482, 1987
47. Poole AR, Alini M, Hollander AP: Cellular biology of cartilage degradation. In, Mechanisms and Models in Rheumatoid Arthritis. Edited by B Henderson, ER Pettipher, JCW Edwards. London, Academic Press, 1995